Edgar Filing: BOSTON SCIENTIFIC CORP - Form FWP

BOSTON SCIENTIFIC CORP Form FWP

December 11, 2009

Coupon Dates

Filed Pursuant to Rule 433 under the Securities Act of 1933 Registration Statement No. 333-163621 Issuer Free Writing Prospectus, dated December 10, 2009

Boston Scientific Corporation

\$2,000,000,000

Senior Notes Offering

Terms and Conditions 5, 10 and 30 Year Fixed Rate Notes

	5-Year	10-Year	30-Year
Issuer	Boston Scientific Corporation	Boston Scientific Corporation	Boston Scientific Corporation
Note Type	Senior Notes	Senior Notes	Senior Notes
Form of Offering	SEC Registered	SEC Registered	SEC Registered
Ratings ¹	Bal (stable outlook) Moody s BBB- (stable outlook) S&P BB+ (positive outlook) Fitch	Ba1 (stable outlook) Moody s BBB- (stable outlook) S&P BB+ (positive outlook) Fitch	Ba1 (stable outlook) Moody s BBB- (stable outlook) S&P BB+ (positive outlook) Fitch
Principal Amount	\$850,000,000	\$850,000,000	\$300,000,000
Trade Date	December 10, 2009	December 10, 2009	December 10, 2009
Settlement Date (T + 2)	December 14, 2009	December 14, 2009	December 14, 2009
Maturity Date	January 15, 2015	January 15, 2020	January 15, 2040
Coupon	4.500% per annum	6.000% per annum	7.375% per annum
Yield	4.567% per annum	6.129% per annum	7.384% per annum
Price to Public ²	99.694%	99.031%	99.879%
Spread	Plus 237.5bps	Plus 262.5bps	Plus 287.5bps
Benchmark Treasury	2.125% UST due November 30, 2014	3.375% UST due November 15, 2019	4.500% UST due August 15, 2039
Benchmark Yield	2.192%	3.504%	4.509%
Net Proceeds to Company (before expenses)	\$847,399,000	\$841,763,500	\$299,637,000

Edgar Filing: BOSTON SCIENTIFIC CORP - Form FWP

	0 0		
	Semi-annually on January 15 and July 15	Semi-annually on January 15 and July 15	Semi-annually on January 15 and July 15
First Coupon Date	July 15, 2010	July 15, 2010	July 15, 2010
Optional Redemption	The greater of:	The greater of:	The greater of:
	100% of the principal amount of the notes to be redeemed, or	100% of the principal amount of the notes to be redeemed, or	100% of the principal amount of the notes to be redeemed, or
	as determined by a Quotation Agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Adjusted Treasury Rate plus 35 basis points plus accrued and unpaid interest on the notes to the redemption date.	as determined by a Quotation Agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Adjusted Treasury Rate plus 40 basis points plus accrued and unpaid interest on the notes to the redemption date.	as determined by a Quotation Agent, the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Adjusted Treasury Rate plus 45 basis points plus accrued and unpaid interest on the notes to the redemption date.
Day Count Basis	30/360	30/360	30/360
Minimum Denominations	US\$2,000 and integral multiples of US\$1,000 in excess of such amount	US\$2,000 and integral multiples of US\$1,000 in excess of such amount	US\$2,000 and integral multiples of US\$1,000 in excess of such amount
CUSIP / ISIN	101137 AJ6 / US101137AJ68	101137 AK3 / US101137AK32	101137 AL1 / US101137AL15
Joint Bookrunners	Banc of America Securities LLC Deutsche Bank Securities Inc. J.P. Morgan Securities Inc. Barclays Capital Inc. BNP Paribas Securities Corp. RBS Securities Inc.	Banc of America Securities LLC Deutsche Bank Securities Inc. J.P. Morgan Securities Inc. Barclays Capital Inc. BNP Paribas Securities Corp. RBS Securities Inc.	Banc of America Securities LLC Deutsche Bank Securities Inc. J.P. Morgan Securities Inc. Barclays Capital Inc. BNP Paribas Securities Corp. RBS Securities Inc.

	5-Year	10-Year	30-Year
Co-Managers	Daiwa Securities America	Daiwa Securities America	Daiwa Securities America
	Inc.	Inc.	Inc.
	Mitsubishi UFJ Securities	Mitsubishi UFJ Securities	Mitsubishi UFJ Securities
	(USA), Inc.	(USA), Inc.	(USA), Inc.
	Mizuho Securities USA Inc.	Mizuho Securities USA Inc.	Mizuho Securities USA Inc.
	Wells Fargo Securities, LLC	Wells Fargo Securities, LLC	Wells Fargo Securities, LLC
	BBVA Securities Inc.	BBVA Securities Inc.	BBVA Securities Inc.
	BNY Mellon Capital	BNY Mellon Capital	BNY Mellon Capital
	Markets, LLC	Markets, LLC	Markets, LLC
	RBC Capital Markets	RBC Capital Markets	RBC Capital Markets
	Corporation	Corporation	Corporation
	Scotia Capital Inc.	Scotia Capital Inc.	Scotia Capital Inc.
	ING Financial Markets LLC	ING Financial Markets LLC	ING Financial Markets LLC
	Allied Irish Banks, p.l.c	Allied Irish Banks, p.l.c	Allied Irish Banks, p.l.c
	Standard Chartered Bank	Standard Chartered Bank	Standard Chartered Bank

Notes:

- 1 A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
- 2 Plus accrued interest, if any, from December 14, 2009.

The Company plans to use the net proceeds of this offering for general corporate purposes, including prepaying a portion of its bank term loan due in April 2011. The Company expects to record a pre-tax charge, not previously anticipated, of approximately \$30 million (approximately \$19 million after tax, or \$0.01 per share) in the fourth quarter associated with the prepayment.

As a result of this offering, the Company s pro forma consolidated ratio of earnings to fixed charges for the nine months ended September 30, 2009 may decrease by more than ten percent.

Because more than 5% of the proceeds of this offering, not including underwriting compensation, may be received by affiliates of the underwriters in this offering, this offering is being conducted in compliance with NASD Rule 2720, as administered by the Financial Industry Regulatory Authority. Pursuant to NASD Rule 2720, the appointment of a qualified independent underwriter is not necessary in connection with this offering, as the offering is of debt securities that are investment grade rated.

THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU

Edgar Filing: BOSTON SCIENTIFIC CORP - Form FWP

SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT WWW.SEC.GOV. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CALLING BANC OF AMERICA SECURITIES LLC TOLL-FREE AT 1-800-294-1322, DEUTSCHE BANK SECURITIES INC. TOLL-FREE AT 1-800-503-4611 OR J.P. MORGAN SECURITIES INC. COLLECT AT 212-834-4533.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.